Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL 3: Infigratinib in Children With Achondroplasia
NCT06164951Phase 3Completed
- Sponsor
- QED Therapeutics
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in achondroplasia (ACH) comparing Infigratinib 0.25 mg/kg/day with Placebo 0.25 mg/kg/day (2 arms). Primary endpoint: Annualized Height Velocity at 52 weeks. Started Nov 2023; status: completed.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT06164951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06164951.